Ozempic is one brand name (Wegovy is the other) for a GLP-1 medication, which is an injectable peptide
When injected, it activates GLP-1 receptors in the pancreas, brain, and stomach
Despite the urgent need for less invasive tests, only one marketed test is available for endometriosis, and the pipeline is limited, with only 14 candidates, 10 of which are still in early development
Ours was among the first, maybe the first study, that was published on GLP-1s in breast cancer, but it was a very small cohort that came out of Memorial Sloan Kettering
Semaglutide (the active ingredient in Ozempic and Wegovy) is a single GLP-1 receptor agonist
Despite their shared origin, Melanotan II and PT-141 differ significantly in their receptor selectivity, physiological effects, intended research focus, and safety considerations